The effectiveness of worry exposure in treating generalized anxiety disorder

Ghasem Shahmoradi*a, Mohsen Dadashib, Zakaria Eskandaric, Mohammad Reza Iravani*d, Samaneh Salimi* and Hajar Jannesarif

aMSc of Clinical Psychology, Psychology Group, School of Education and Psychology, Tabriz University, Tabriz, Iran.
bPhd student of clinical psychology, Tehran University of Medical Sciences, Tehran, Iran
cMSc in clinical psychology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
dAssistant Professor, Department of Social Work, Islamic Azad University Khomeinishahr Branch, Daneshjou Blvd, Iran
eMS Student, Counseling Department, Psychological and Education Science Faculty University of Isfahan, Isfahan, Iran
fMS Student, Counseling Department, Islamic Azad University of Khomeinishahr, Khomeinishahr Branch, Daneshjou Blvd, Iran

ABSTRACT

Worry exposure (WE) is a core of cognitive-behavioral treatment for generalized anxiety disorder (GAD). The present study was carried out to examine the efficacy of WE in treating patients with GAD. Three patients with GAD were selected using Structured Clinical Interview for DSM-IV (SCID) based on disorders axis I. Subjects were selected using purposeful sampling, and underwent the treatment after gaining treatment needs. Multiple baseline experimental single case study was used as the method of the present study. The treatment program was carried out for 8 weekly sessions, with a follow up period of 3 months later treatment ending. Subjects completed Pennsylvania State Worry Questionnaire (PSWQ) and Cognitive Avoidance Questionnaire (CAQ). Research findings represented that WE decreased the intensity of GAD symptoms: Pathologic worry and cognitive avoidance. WE has suitable efficacy in treating Generalized Anxiety Disorder and it maintains suitable efficacy in treating GAD.

Keywords:
Worry exposure
Generalized Anxiety Disorder
Cognitive Avoidance
Worry

1. Introduction

Generalized anxiety disorder (GAD) is normally defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) as “the presence of persistent, excessive anxiety and worry about a number of events and occurring on more days than not for >6 months”. In addition, the patient has to experience, at least, three of the following six symptoms including restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, and sleep disturbance. There are different types of patients who may experience many of these symptoms; nevertheless, due to the DSM-IV requirement of excessive
worries with symptoms being present for >6 months will not recognize this diagnosis despite experiencing substantial impairment in functioning (Bienvenu et al., 1998).

Overall, one of popular psychosocial treatments for the treatment of GAD is cognitive-behavioral therapy (CBT). The components of this therapy may be different to include the following: education about the symptoms and causes of anxiety, cognitive restructuring, Worry exposure, applied relaxation, increasing awareness, learning to monitor of anxious symptoms presenting as physical symptoms, and the automatic thoughts of worry created from situational and behavioral cues. Patients are taught to manage these symptoms through training in arousal reduction techniques (Roemer & Orsillo, 2002).

Worry exposure (WE) is a core of cognitive-behavioral treatment for generalized anxiety disorder (GAD) (Borkovec & Newman, 1999; Borkovec et al., 2004). Past meta-analyses evaluating the effectiveness of CBT for GAD implemented general measures of anxiety to evaluate symptom severity and improvement. However, these studies do not sufficient support on whether CBT substantially reduces the cardinal symptom of GAD: pathological worry. Covin et al. (2008) performed a meta-analysis to evaluate relevant outcome studies, including the use of the Penn State Worry Questionnaire as the primary outcome variable. They reported a large overall effect size (ES) moderated by age and modality of treatment. Specifically, the largest gains were detected for younger adults and for individual treatment. Analyses also disclosed overall maintenance of gains at 6- and 12-month follow-up.

According to Hoyer et al. (2009), WE is a core element of cognitive-behavioral treatment for GAD. Hoyer et al. (2009) examined whether WE alone is as efficacious as the empirically supported stand-alone treatment for GAD, applied relaxation (AR). They reported that a stand-alone exposure in sensu technique, WE, could be efficacious in the treatment of GAD. Kessler et al. (2005) investigated prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.

Linden et al. (2004) performed a controlled clinical trial to evaluate the efficacy of CBT treatment in outpatients with pure GAD who were treated by a therapist working in routine care. They concluded that CBT could an effective technique of treatment for GAD and differences between control and treatment group were comparable to or larger than those reported in studies on antidepressant drugs. Liss et al. (2005) performed a sensory processing sensitivity and its relationship with parental bonding, anxiety, and depression.


Alilou et al. (2011) compared the intolerance of uncertainty, cognitive avoidance, negative problem orientation and positive beliefs about worry in generalized anxiety disorder patients with normal individuals. Ballenger et al. (2001) discussed the views of the International Consensus Group on Depression and Anxiety and reported that cognitive-behavioral therapy was the preferred form of psychotherapy for GAD, although when GAD is comorbid with depression, pharmacotherapy is increasingly indicated (Beck et al., 1996; Bennett-Levy et al., 2005).

Davidson (2004) implemented benzodiazepines in social anxiety disorder, GAD, and posttraumatic stress disorder and proposed some suggestion to reduce the effect of social anxiety disorder. Dugas
and Robichaud (2007) presented a comprehensive review on cognitive-behavioral treatment for
generalized anxiety disorder and discussed the challenges are faced from science perspective to
disorder. Hamidpour (2008) examined the efficacy and effectiveness of mindfulness-based cognitive
therapy (Tyrer, 1999) in treatment and presentation of relapse and recurrence of dysthymia.

The organization of this paper is organized as follows. We first present details of our different tests
we implement on three patients in section 2. Section 3 presents details of our computational results
and finally concluding remarks are given in the last to summarize the contribution of this paper.

2. The proposed method

The present study examines the efficacy of WE in treating patients with GAD. Three patients with
GAD were selected using Structured Clinical Interview for DSM-IV (SCID) based on disorders axis
I. Table 1 shows personal characteristics of the patients.

<table>
<thead>
<tr>
<th>Group</th>
<th>Gender</th>
<th>Age</th>
<th>Marital status</th>
<th>Level of Education</th>
<th>Medication</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Female</td>
<td>45</td>
<td>Married</td>
<td>Master’s degree</td>
<td>Drug medication</td>
</tr>
<tr>
<td>B</td>
<td>Female</td>
<td>36</td>
<td>Single</td>
<td>Diploma</td>
<td>No medication</td>
</tr>
<tr>
<td>C</td>
<td>Male</td>
<td>24</td>
<td>Single</td>
<td>Bachelor of science</td>
<td>Drug medication</td>
</tr>
</tbody>
</table>

Subjects are selected using purposeful sampling, and underwent the treatment after gaining treatment
needs. Multiple baseline experimental single case study is then used as the method of the present
study. The treatment program is carried out for 8 weekly sessions, with a follow up period of 3
months later treatment ending. Subjects completed Pennsylvania State Worry Questionnaire (PSWQ)
and Cognitive Avoidance Questionnaire (CAQ).

3. The results

In this section, we present details of our findings on the experiments. Table 2 demonstrates the results
of PSWQ and CAQ on three samples.

<table>
<thead>
<tr>
<th></th>
<th>A</th>
<th>B</th>
<th>C</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSWQ (based-line)</td>
<td>70</td>
<td>65</td>
<td>63</td>
</tr>
<tr>
<td>PSWQ (first session)</td>
<td>96</td>
<td>62</td>
<td>60</td>
</tr>
<tr>
<td>PSWQ (fourth session)</td>
<td>52</td>
<td>47</td>
<td>41</td>
</tr>
<tr>
<td>PSWQ (eighth session)</td>
<td>42</td>
<td>32</td>
<td>37</td>
</tr>
<tr>
<td>% of recovery</td>
<td>40%</td>
<td>51%</td>
<td>41%</td>
</tr>
<tr>
<td>Total % of recovery</td>
<td>44%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAQ (based-line)</td>
<td>94</td>
<td>80</td>
<td>77</td>
</tr>
<tr>
<td>CAQ (first session)</td>
<td>91</td>
<td>79</td>
<td>74</td>
</tr>
<tr>
<td>CAQ (fourth session)</td>
<td>63</td>
<td>49</td>
<td>55</td>
</tr>
<tr>
<td>CAQ (eighth session)</td>
<td>52</td>
<td>43</td>
<td>40</td>
</tr>
<tr>
<td>% of recovery</td>
<td>52%</td>
<td>46%</td>
<td>48%</td>
</tr>
<tr>
<td>Total % of recovery</td>
<td></td>
<td>46%</td>
<td></td>
</tr>
</tbody>
</table>

In order to have a better understanding on comparing the effect of different tests on three patients, we
have depicted them and Fig. 1 demonstrates the results of PSWQ and CAQ tests.
As we can observe from the results of Table 2 and Fig. 1, the level of PSWQ and CAQ among three patients have been reduced after the eighth sessions. We have measured the level of STAI-T and BDI-II for all three patients and the results are summarized in Fig. 2 and Table 3.

**Table 3**
The summary of the results of STAI-T and BDI-II on three samples

<table>
<thead>
<tr>
<th></th>
<th>A</th>
<th>B</th>
<th>C</th>
</tr>
</thead>
<tbody>
<tr>
<td>STAI-T (based-line)</td>
<td>52</td>
<td>51</td>
<td>52</td>
</tr>
<tr>
<td>STAI-T (first session)</td>
<td>49</td>
<td>50</td>
<td>49</td>
</tr>
<tr>
<td>STAI-T (fourth session)</td>
<td>41</td>
<td>31</td>
<td>41</td>
</tr>
<tr>
<td>STAI-T (eighth session)</td>
<td>28</td>
<td>21</td>
<td>28</td>
</tr>
<tr>
<td>% of recovery</td>
<td>46%</td>
<td>59%</td>
<td>46%</td>
</tr>
<tr>
<td>Total % of recovery</td>
<td>52%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BDI-II (based-line)</td>
<td>29</td>
<td>34</td>
<td>29</td>
</tr>
<tr>
<td>BDI-II (first session)</td>
<td>26</td>
<td>33</td>
<td>26</td>
</tr>
<tr>
<td>BDI-II (fourth session)</td>
<td>16</td>
<td>21</td>
<td>16</td>
</tr>
<tr>
<td>BDI-II (eighth session)</td>
<td>10</td>
<td>15</td>
<td>10</td>
</tr>
<tr>
<td>% of recovery</td>
<td>66%</td>
<td>56%</td>
<td>66%</td>
</tr>
<tr>
<td>Total % of recovery</td>
<td></td>
<td>61%</td>
<td></td>
</tr>
</tbody>
</table>

**Fig. 2.** The results of STAI-T and BDI-II tests
Again, we can observe from the results of Table 3 and Fig. 3, the level of STAI-T and BDI-II among three patients have been reduced after the eighth sessions.

4. Conclusion

This is the second study investigating the efficacy of WE as stand-alone treatment for patients with DSM-IV GAD. The patients demonstrated distinct improvements on all outcome measures in active treatment conditions. Therefore, symptoms of anxiety and depression, excessive worrying and Cognitive Avoidance were reduced. These improvements appeared stabile, as marked by 3-month follow-up assessments. One particularly interesting finding was that all secondary outcome measures designed to evaluate cognitive change were efficiently reduced despite the fact that no clear cognitive intervention was applied. These results are consistent with other studies that question the necessity of clear cognitive interventions. Although the assumed pathways through which WE brought about change clearly differ, they may have a higher-level form in common. For instance, treatment enable the patient to feel more competent when confronted with upcoming worries.

This form of competency is often described as self-efficacy and may indirectly impact related (negative) beliefs about worrying as well the necessity to control one’s own thinking. Our analyses did not disclose any moderating impact of psychiatric comorbidity on the treatment outcome, as the improvements were maintained even after controlling for another comorbid disorders. However, this does not mean that comorbid disorders are neutral for the therapeutic effect. Moderate and severe forms of depression are seen as a contraindication for WE and patients reaching the respective degree of severity of depression were excluded from the present study. Consequently, our results only confirm the view that WE can be applied successfully when mild depression or other comorbid conditions such as anxiety disorders are present. Furthermore, other potential moderating such as treatment expectations or the quality of the therapeutic alliance where not found to influence the results in a significant way.

In summary, in this second trial of WE as a stand-alone treatment for GAD we found this method to be efficacious. Although WE represent effective principles of change in GAD, this treatment should be further developed more systematically combined with other treatment components.

Acknowledgment

The authors would like to thank the anonymous referees for constructive comments on earlier version of this work.

References

Alilou, M., Shahjooyi T, & Hashemi Z. (2011). The Comparison of intolerance of uncertainty, cognitive avoidance, negative problem orientation and positive beliefs about worry in generalized anxiety disorder patients with normal individuals. *Journal of Tabriz University Psychology*, 5(20), [In Persian].


